Cargando…
Health-related Quality of Life Outcomes of Adalimumab for Patients With Rheumatoid Arthritis in Korea
OBJECTIVE: Rheumatoid arthritis (RA) is a chronic, progressive, autoimmune disorder that impairs patients’ overall health-related quality of life (HRQOL) In this study, we evaluated the effect of adalimumab in Korean patients with active RA on HRQOL. METHODS: Patients included in the study had moder...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean College of Rheumatology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324887/ https://www.ncbi.nlm.nih.gov/pubmed/37476011 http://dx.doi.org/10.4078/jrd.2021.28.2.68 |
_version_ | 1785069195664293888 |
---|---|
author | Lee, Myeung-su Lee, Chang Hoon Lee, Hye Soon Sung, Yoon-Kyoung Choi, Jung Ran Park, Kyungsu Lim, Mi-Kyoung Choi, Byoong Yong Kim, Hyoun-Ah Choi, Seung Won Lee, Yusun Yoo, Wan-Hee |
author_facet | Lee, Myeung-su Lee, Chang Hoon Lee, Hye Soon Sung, Yoon-Kyoung Choi, Jung Ran Park, Kyungsu Lim, Mi-Kyoung Choi, Byoong Yong Kim, Hyoun-Ah Choi, Seung Won Lee, Yusun Yoo, Wan-Hee |
author_sort | Lee, Myeung-su |
collection | PubMed |
description | OBJECTIVE: Rheumatoid arthritis (RA) is a chronic, progressive, autoimmune disorder that impairs patients’ overall health-related quality of life (HRQOL) In this study, we evaluated the effect of adalimumab in Korean patients with active RA on HRQOL. METHODS: Patients included in the study had moderate to severe active RA that did not respond to conventional drugs with a Disease Activity Score of 28 joints >32 and were biologics-naïve All patients received adalimumab 40 mg subcutaneously every other week and were followed for 24 weeks The primary endpoint was the change in baseline Health Assessment Questionnaire Disability Index (HAQ-DI) score at week 24 Secondary endpoints were changes in the EuroQol 5-dimension 3-Level (EQ-5D-3L) baseline score and Short Form 36-Item Health Survey (SF-36) domain scores at weeks 12 and 24 and change in baseline HAQ-DI score at week 12. RESULTS: In total, 91 Korean patients were included Ninety-three percent of patients were in high disease activity with a baseline mean DAS28 value of 61 within all patients The mean change from baseline in HAQ-DI scores were −046 at week 12 and∼067 at week 24 (p<00001) Additionally, EQ-5D-3L score at weeks 12 and 24 had significantly improved (p<00001) compared to baseline SF-36 at weeks 12 and 24 had significantly improved (p<00001, p=00001) compared to baseline. CONCLUSION: Treatment with adalimumab resulted in significant improvement in HAQ-DI, EQ-5D-3L, and SF-36 scores at 12 and 24 weeks in Korean RA patient. |
format | Online Article Text |
id | pubmed-10324887 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Korean College of Rheumatology |
record_format | MEDLINE/PubMed |
spelling | pubmed-103248872023-07-20 Health-related Quality of Life Outcomes of Adalimumab for Patients With Rheumatoid Arthritis in Korea Lee, Myeung-su Lee, Chang Hoon Lee, Hye Soon Sung, Yoon-Kyoung Choi, Jung Ran Park, Kyungsu Lim, Mi-Kyoung Choi, Byoong Yong Kim, Hyoun-Ah Choi, Seung Won Lee, Yusun Yoo, Wan-Hee J Rheum Dis Original Article OBJECTIVE: Rheumatoid arthritis (RA) is a chronic, progressive, autoimmune disorder that impairs patients’ overall health-related quality of life (HRQOL) In this study, we evaluated the effect of adalimumab in Korean patients with active RA on HRQOL. METHODS: Patients included in the study had moderate to severe active RA that did not respond to conventional drugs with a Disease Activity Score of 28 joints >32 and were biologics-naïve All patients received adalimumab 40 mg subcutaneously every other week and were followed for 24 weeks The primary endpoint was the change in baseline Health Assessment Questionnaire Disability Index (HAQ-DI) score at week 24 Secondary endpoints were changes in the EuroQol 5-dimension 3-Level (EQ-5D-3L) baseline score and Short Form 36-Item Health Survey (SF-36) domain scores at weeks 12 and 24 and change in baseline HAQ-DI score at week 12. RESULTS: In total, 91 Korean patients were included Ninety-three percent of patients were in high disease activity with a baseline mean DAS28 value of 61 within all patients The mean change from baseline in HAQ-DI scores were −046 at week 12 and∼067 at week 24 (p<00001) Additionally, EQ-5D-3L score at weeks 12 and 24 had significantly improved (p<00001) compared to baseline SF-36 at weeks 12 and 24 had significantly improved (p<00001, p=00001) compared to baseline. CONCLUSION: Treatment with adalimumab resulted in significant improvement in HAQ-DI, EQ-5D-3L, and SF-36 scores at 12 and 24 weeks in Korean RA patient. Korean College of Rheumatology 2021-04-01 2021-04-01 /pmc/articles/PMC10324887/ /pubmed/37476011 http://dx.doi.org/10.4078/jrd.2021.28.2.68 Text en Copyright © 2021 by The Korean College of Rheumatology. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Lee, Myeung-su Lee, Chang Hoon Lee, Hye Soon Sung, Yoon-Kyoung Choi, Jung Ran Park, Kyungsu Lim, Mi-Kyoung Choi, Byoong Yong Kim, Hyoun-Ah Choi, Seung Won Lee, Yusun Yoo, Wan-Hee Health-related Quality of Life Outcomes of Adalimumab for Patients With Rheumatoid Arthritis in Korea |
title | Health-related Quality of Life Outcomes of Adalimumab for Patients With Rheumatoid Arthritis in Korea |
title_full | Health-related Quality of Life Outcomes of Adalimumab for Patients With Rheumatoid Arthritis in Korea |
title_fullStr | Health-related Quality of Life Outcomes of Adalimumab for Patients With Rheumatoid Arthritis in Korea |
title_full_unstemmed | Health-related Quality of Life Outcomes of Adalimumab for Patients With Rheumatoid Arthritis in Korea |
title_short | Health-related Quality of Life Outcomes of Adalimumab for Patients With Rheumatoid Arthritis in Korea |
title_sort | health-related quality of life outcomes of adalimumab for patients with rheumatoid arthritis in korea |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324887/ https://www.ncbi.nlm.nih.gov/pubmed/37476011 http://dx.doi.org/10.4078/jrd.2021.28.2.68 |
work_keys_str_mv | AT leemyeungsu healthrelatedqualityoflifeoutcomesofadalimumabforpatientswithrheumatoidarthritisinkorea AT leechanghoon healthrelatedqualityoflifeoutcomesofadalimumabforpatientswithrheumatoidarthritisinkorea AT leehyesoon healthrelatedqualityoflifeoutcomesofadalimumabforpatientswithrheumatoidarthritisinkorea AT sungyoonkyoung healthrelatedqualityoflifeoutcomesofadalimumabforpatientswithrheumatoidarthritisinkorea AT choijungran healthrelatedqualityoflifeoutcomesofadalimumabforpatientswithrheumatoidarthritisinkorea AT parkkyungsu healthrelatedqualityoflifeoutcomesofadalimumabforpatientswithrheumatoidarthritisinkorea AT limmikyoung healthrelatedqualityoflifeoutcomesofadalimumabforpatientswithrheumatoidarthritisinkorea AT choibyoongyong healthrelatedqualityoflifeoutcomesofadalimumabforpatientswithrheumatoidarthritisinkorea AT kimhyounah healthrelatedqualityoflifeoutcomesofadalimumabforpatientswithrheumatoidarthritisinkorea AT choiseungwon healthrelatedqualityoflifeoutcomesofadalimumabforpatientswithrheumatoidarthritisinkorea AT leeyusun healthrelatedqualityoflifeoutcomesofadalimumabforpatientswithrheumatoidarthritisinkorea AT yoowanhee healthrelatedqualityoflifeoutcomesofadalimumabforpatientswithrheumatoidarthritisinkorea |